SCHEMBL7042872

SCHEMBL7042872

Cc1ccc(-c2ccc(CNC(=O)c3cc(NC(=O)c4cccc(C)c4N4CCCCC4)cn3C)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.43
TP53 P04637 2/20 0.43
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
THRB P10828 1/20 0.42
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
LMNA P02545 2/20 0.41
GAA P10253 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
DNM1L O00429 1/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7041929 0.87 L3MBTL1 (0.50) POLBTP53MAPTALDH1A1HPGD
SCHEMBL6674613 0.87 MAPT (0.41) POLBTP53CRHBPCRHR2MAPT
SCHEMBL7039859 0.81 CHRNB2 (0.47) POLBTP53ALDH1A1HPGDLMNA
SCHEMBL7036532 0.79 POLB (0.54) POLBTP53ALDH1A1LMNAGAA
SCHEMBL7039230 0.79 CHRNB2 (0.51) POLBTP53ALDH1A1HPGDLMNA
SCHEMBL7037234 0.78 RXFP1 (0.46) POLBALDH1A1HPGDLMNAL3MBTL1
SCHEMBL7041084 0.77 LMNA (0.46) POLBTP53MAPTALDH1A1LMNA
SCHEMBL7039202 0.77 ALDH1A1 (0.64) POLBALDH1A1HPGDLMNAGAA
SCHEMBL7041358 0.76 ALDH1A1 (0.51) POLBTP53ALDH1A1HPGDLMNA
SCHEMBL7038646 0.75 KMT2A (0.54) POLBMAPTALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-08-28 US disclosed
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals APOB, LIPC, MTPN POLB 2105/4885TP53 3704/4885CRHBP 1237/4885
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions MTTP, CETP, CES1 POLB 4365/4885TP53 4699/4885CRHBP 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.